
    
      This is a two-step, open-label, multi-center, dose escalation Phase 1 study in which RAD001
      is administered in combination with carboplatin and paclitaxel (CP) in Step 1 as well as
      carboplatin, paclitaxel, and bevacizumab (CPB) in Step 2 in patients with advanced
      (unresectable or metastatic) NSCLC not treated previously with systemic therapy for advanced
      disease
    
  